From GlobeNewswire:

Apollomics Inc. is taking part in the 2024 Virtual Oncology Conference. The company is focused on developing cancer treatments that can be combined with other options and target specific molecular pathways. Apollomics has a pipeline of nine drug candidates, including vebreltinib for non-small cell lung cancer and uproleselan for acute myeloid leukemia.

Access to the webcast of the fireside chat with Guo-Liang Yu and Sanjeev Redkar can be arranged through a B. Riley Securities sales representative. A replay of the event will be available on the Apollomics website.

A cautionary statement outlines the potential risks and uncertainties facing the company. Forward-looking statements are based on current expectations and assumptions about future events. Apollomics urges caution when interpreting its statements.

Investor Relations and Media Relations contacts are available for further information and inquiries. Peter Vozzo and Sean Leous can be reached for more details on the company and its participation in the 2024 Virtual Oncology Conference.



Read more: Apollomics to Participate in a Fireside Chat at the B.